Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.5 CHF | +3.25% | +9.34% | +26.06% |
03/05 | Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024 | CI |
09/04 | Basilea Pharmaceutica Receives Grant for Antibiotics Program | MT |
Sales 2024 * | 182M 200M 16.74B | Sales 2025 * | 206M 227M 18.94B | Capitalization | 537M 593M 49.48B |
---|---|---|---|---|---|
Net income 2024 * | 23M 25.37M 2.12B | Net income 2025 * | 35M 38.61M 3.22B | EV / Sales 2024 * | 3.27 x |
Net Debt 2024 * | 57.88M 63.84M 5.33B | Net Debt 2025 * | 12.51M 13.8M 1.15B | EV / Sales 2025 * | 2.67 x |
P/E ratio 2024 * |
22.3
x | P/E ratio 2025 * |
18.8
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
1 day | +3.25% | ||
1 week | +9.34% | ||
Current month | +12.66% | ||
1 month | +10.01% | ||
3 months | +19.62% | ||
6 months | +24.48% | ||
Current year | +26.06% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 01/14/01 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 01/09/01 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 01/18/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 27/17/27 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 01/22/01 |
Director/Board Member | 69 | 09/13/09 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 746 M€ | -.--% | - | |
0.00% | 10 M€ | -3.35% | - | |
0.00% | 34 M€ | +3.53% | - |
Date | Price | Change | Volume |
---|---|---|---|
14/24/14 | 44.5 | +3.25% | 40,475 |
13/24/13 | 43.1 | +0.35% | 23,536 |
10/24/10 | 42.95 | +0.23% | 32,989 |
08/24/08 | 42.85 | +5.28% | 61,838 |
07/24/07 | 40.7 | +1.24% | 17,347 |
Delayed Quote Swiss Exchange, May 14, 2024 at 09:00 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.06% | 573M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- BSLN Stock